Methylene blue for treatment of hospitalized COVID-19 patients: a randomized, controlled, open-label clinical trial, phase 2

3/8 Late treatment study

Hamidi-Alamdari et al., Clinical and Translational Investigation, doi:10.24875/RIC.21000028 (Peer Reviewed)
Methylene blue for treatment of hospitalized COVID-19 patients: a randomized, controlled, open-label clinical trial, phase 2

Source PDF Share Tweet

RCT 80 hospitalized patients with severe COVID-19, 40 treated with methylene blue + vitamin C + N-acetyl cysteine, showing lower mortality, shorter hospitalization, and significantly improved SpO₂ and respiratory distress with treatment. NCT04370288.

Hamidi-Alamdari et al., 3/8/2021, Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 23 authors, this trial uses multiple treatments in the treatment arm (combined with methylene blue and N-acetyl cysteine) - results of individual treatments may vary.

risk of death, 44.4% lower, RR 0.56, p = 0.38, treatment 5 of 40 (12.5%), control 9 of 40 (22.5%).

hospitalization time, 37.6% lower, relative time 0.62, p = 0.004, treatment 40, control 40.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 26 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit